Results 71 to 80 of about 5,421 (159)

Epidemiology and clinical significance of carbapenemases in Australia: a narrative review

Internal Medicine Journal, Volume 54, Issue 4, Page 535-544, April 2024.
Abstract Carbapenemase‐producing gram‐negative bacteria (CP‐GNB) infections threaten public health with high mortality, morbidity and treatment costs. Although frequencies remain low in Australia (total number of CP‐GNB infections reported was 907 in 2022), blaIMP‐4 has established low levels of endemicity in many states.
Abdullah Tarik Aslan, David L. Paterson
wiley   +1 more source

Multidrug-Resistant Acinetobacter baumannii: Resistance Mechanisms, Emerging Therapies, and Prevention—A Narrative Review

Antibiotics
Acinetobacter baumannii is a leading intensive care unit (ICU) pathogen associated with high rates of carbapenem resistance and poor clinical outcomes.
Ioana Adelina Stoian, Bianca Balas Maftei, Carmen-Elena Florea, Alexandra Rotaru, Constantin Aleodor Costin, Maria Antoanela Pasare, Radu Crisan Dabija, Carmen Manciuc   +7 more
doaj   +1 more source

in a critically ill burn patient: clinical challenges and molecular characterization

, 2023
Background Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are associated with high mortality rates. The optimal treatment regimen for CRAB has not been defined.
Riccardi, Niccolò, Federica Limongi, Tiseo, Giusy, Nicastro, Manuela, Simona Barnini, Valentina Galfo, Barnini, Simona, Giordano, Cesira, Galfo, Valentina, Niccolò Riccardi, Limongi, Federica, Manuela Nicastro, Giusy Tiseo, Leonildi, Alessandro, Cesira Giordano, Alessandro Leonildi, Marco Falcone, Falcone, Marco   +17 more
core   +1 more source

Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline

Microorganisms
Acinetobacter baumannii complex (ABC) can result in a panoply of severe syndromes, including pneumonia and septic shock. Options available for treating infections caused by ABC and, more importantly, by carbapenem-resistant ABC (CRAB) are limited because
Noayna Arshad, Wael Azzam, Marya D. Zilberberg, Andrew F. Shorr   +3 more
doaj   +1 more source

New β-Lactam/β-Lactamase Inhibitor Combination Antibiotics

Pathogens
The growing problem of infections due to pathogens with antimicrobial resistance, especially Gram-negative bacteria, has led to the development of new β-lactam/β-lactamase inhibitor combination antibiotics.
Maria Sargianou, Panagiotis Stathopoulos, Christos Vrysis, Iva D. Tzvetanova, Matthew E. Falagas   +4 more
doaj   +1 more source

Sulbactam-durlobactam susceptibility among cefiderocol heteroresistant Acinetobacter

ABSTRACT The ATTACK clinical trial for treatment of carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB) isolates determined treatment with sulbactam-durlobactam to be efficacious and safe.
Bikash Bogati, Tugba Ozturk, Sarah W. Satola, David S. Weiss   +3 more
openaire   +1 more source

Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies

Microorganisms
This review provides an overview of recent research and advancements in infection prevention and the treatment of drug-resistant bacterial diseases.
Majid Eslami, Amirabbas Safaripour, Seyedeh Zahra Banihashemian, Sahar Nikjoo Niaragh, Mohammad Amin Hemmati, Arefeh Shojaeian, Setayesh Fakhariyan, Atiye Rabbani, Valentyn Oksenych   +8 more
doaj   +1 more source

Case Report: Successful salvage therapy with sulbactam-durlobactam combined with meropenem for carbapenem-resistant Acinetobacter baumannii bloodstream infection in a child after failure of allogeneic hematopoietic stem cell transplantation

Frontiers in Pediatrics
Bloodstream infections (BSI) caused by carbapenem-resistant Acinetobacter baumannii (CRAB) constitute a serious complication in patients undergoing hematopoietic stem cell transplantation (HSCT), with pediatric patients facing particularly formidable ...
Qian Zhang, Chunjing Wang, Zhiheng Ding, Jiayi Lyu, Yu Zhang, Fangyuan Lai, Ruihao Zheng, Sixi Liu   +7 more
doaj   +1 more source

In vitro interactions of sulbactam/durlobactam in combination with meropenem, ceftazidime/avibactam, piperacillin/tazobactam, cefiderocol and fosfomycin against carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates

: We evaluated in vitro activity of sulbactam/durlobactam in combination with different antimicrobials against Carbapenem-Resistant Acinetobacter baumannii (CRAB) clinical isolates with different susceptibility profiles, including sulbactam/durlobactam ...
Zocche, Giulia, Lewis, Russell E, Tascini, Carlo, Gaibani, Paolo, Bianco, Gabriele   +4 more
core   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source